4.0 Article

Can understanding the neurobiology of body dysmorphic disorder (BDD) inform treatment?

Journal

AUSTRALASIAN PSYCHIATRY
Volume 23, Issue 4, Pages 361-364

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/1039856215591327

Keywords

body dysmorphic disorder; MRI; faces

Categories

Funding

  1. Eli Lilly
  2. Janssen Cilag
  3. Roche
  4. Allergen
  5. Bristol-Myers Squibb
  6. Pfizer
  7. Lundbeck
  8. Astra Zeneca
  9. Hospira

Ask authors/readers for more resources

Objectives: We aim to provide a clinically focused review of the neurobiological literature in body dysmorphic disorder (BDD), with a focus on structural and functional neuroimaging. Conclusions: There has been a recent influx of studies examining the underlying neurobiology of BDD using structural and functional neuroimaging methods. Despite obvious symptom similarities with obsessive-compulsive disorder (OCD), no study to date has directly compared the two groups using neuroimaging techniques. Studies have established that there are limbic and visual cortex abnormalities in BDD, in contrast to fronto-striatal differences in OCD. Such data suggests affect or visual training maybe useful in BDD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available